We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Bristol-Myers Squibb Company is placed second among the best cancer stocks on our list.
TheFly reported on January 9 that Scotiabank analyst Louise Chen raised BMY’s price target to $60 from $53 while maintaining a Sector Perform rating. According to the analyst, investors find the stock appealing because to its low valuation and a “catalyst-rich” 2026.
Separately, on January 12, Bristol-Myers Squibb Company (NYSE:BMY) announced that its Phase 3 SCOUT-HCM trial, which assessed Camzyos (mavacamten) in teenagers with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), yielded positive topline results. With a safety profile comparable to that of adults, the study, the first Phase 3 evaluation of a cardiac myosin inhibitor in patients with oHCM aged 12 to <18, fulfilled its primary and many secondary endpoints.
Bristol-Myers Squibb Company is a global biopharmaceutical leader in oncology, advancing innovative immuno-oncology and targeted therapies across solid tumors and hematologic malignancies, supported by a deep clinical pipeline and a strong legacy in cancer research and development.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
Hedge Fund Resource Center